BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 21057537)

  • 1. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.
    Rao X; Di Leva G; Li M; Fang F; Devlin C; Hartman-Frey C; Burow ME; Ivan M; Croce CM; Nephew KP
    Oncogene; 2011 Mar; 30(9):1082-97. PubMed ID: 21057537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
    Wang B; Li D; Rodriguez-Juarez R; Farfus A; Storozynsky Q; Malach M; Carpenter E; Filkowski J; Lykkesfeldt AE; Kovalchuk O
    BMC Cancer; 2018 Aug; 18(1):817. PubMed ID: 30103729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
    Zhou Q; Zeng H; Ye P; Shi Y; Guo J; Long X
    Anticancer Drugs; 2018 Jul; 29(6):539-548. PubMed ID: 29557813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
    Long X; Fan M; Bigsby RM; Nephew KP
    Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
    Fan M; Yan PS; Hartman-Frey C; Chen L; Paik H; Oyer SL; Salisbury JD; Cheng AS; Li L; Abbosh PH; Huang TH; Nephew KP
    Cancer Res; 2006 Dec; 66(24):11954-66. PubMed ID: 17178894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.
    Jiang Z; Guo J; Shen J; Jin M; Xie S; Wang L
    J Exp Clin Cancer Res; 2012 May; 31(1):42. PubMed ID: 22553917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
    Song RX; Chen Y; Zhang Z; Bao Y; Yue W; Wang JP; Fan P; Santen RJ
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):219-30. PubMed ID: 19815064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
    Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
    J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
    Long X; Fan M; Nephew KP
    Cancer Biol Ther; 2010 Mar; 9(5):389-96. PubMed ID: 20061804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
    Masri S; Liu Z; Phung S; Wang E; Yuan YC; Chen S
    Breast Cancer Res Treat; 2010 Nov; 124(1):89-99. PubMed ID: 20054641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
    Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
    J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of EGFR and c-ABL suppresses the growth of fulvestrant-resistant breast cancer cells through miR-375-autophagy axis.
    Liu L; Shen W; Zhu Z; Lin J; Fang Q; Ruan Y; Zhao H
    Biochem Biophys Res Commun; 2018 Apr; 498(3):559-565. PubMed ID: 29522716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.
    Morrison MM; Williams MM; Vaught DB; Hicks D; Lim J; McKernan C; Aurisicchio L; Ciliberto G; Simion C; Sweeney C; Cook RS
    Oncogene; 2016 Mar; 35(9):1143-52. PubMed ID: 26148232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells.
    Shaw LE; Sadler AJ; Pugazhendhi D; Darbre PD
    J Steroid Biochem Mol Biol; 2006 Apr; 99(1):19-32. PubMed ID: 16533599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.
    Karam M; Bièche I; Legay C; Vacher S; Auclair C; Ricort JM
    J Cell Mol Med; 2014 Dec; 18(12):2536-52. PubMed ID: 25287328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion.
    JavanMoghadam S; Weihua Z; Hunt KK; Keyomarsi K
    Cell Cycle; 2016 Jun; 15(12):1579-90. PubMed ID: 27049344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.
    Manavalan TT; Teng Y; Litchfield LM; Muluhngwi P; Al-Rayyan N; Klinge CM
    PLoS One; 2013; 8(4):e62334. PubMed ID: 23626803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
    Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; Medema RH; Hartman J; Lykkesfeldt AE; Lam EW
    Oncogene; 2010 May; 29(20):2983-95. PubMed ID: 20208560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.